Epoxide Hydrolase
Epoxide hydrolases (EH) present in all living organisms. The mammalian soluble epoxide hydrolase (sEH) is a 120 kDa dimer of two identical 62.5 kDa monomers arranged in an anti-parallel fashion. It is mostly expressed in the liver, kidneys, brain, endothelium, and at lesser levels in other tissues. Inflammation and pain are major components of many disease states. Mammalian sEH inhibition reduces blood pressure, inflammation and pain. The anti-inflammatory activities of sEH inhibitors occur in part through the NF-κB mediated down-regulation of COX2 transcription, resulting in lower production of pro-inflammatory prostaglandins such as PGE2 and PGD2.
All Product Categories
-
Epoxide Hydrolase Related Products (94)
Related Products (94)
-
Antibodies (1)
-
Dual FAAH/sEH-IN-1
0 ImagesCat. No.: HY-144738CAS No.: 2756099-59-7Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
-
COX-2/sEH-IN-1
0 ImagesCat. No.: HY-146704CAS No.: 2474977-38-1COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
-
10,11-EDT
0 ImagesCat. No.: HY-N12528CAS No.: 2763501-00-210,11-EDT, a soluble epoxide hydrolase (sEH) substrate, is a metabolic product of adrenic acid. 10,11-EDT is an endothelium-derived hyperpolarizing factor with strong vasorelaxant effects.
-
Hydroxytyrosol 1-O-glucoside
0 ImagesCat. No.: HY-169750CAS No.: 76873-99-9Synonyms: Dopaol glucosideHydroxytyrosol 1-O-glucoside (Dopaol glucoside) is a glycoside with antioxidant activity. Hydroxytyrosol 1-O-glucoside is also an epoxide hydrolase 2 inhibitor.
-
sEH inhibitor-3
0 ImagesCat. No.: HY-146643CAS No.: 1809885-35-5sEH inhibitor-3 (compound 35) is a potent and orally active soluble epoxide hydrolase (sEH) inhibitor with a Ki of 0.75 nM for human sEH.
-
sEH inhibitor-14
0 ImagesCat. No.: HY-148573CAS No.: 2890221-26-6sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC50=0.39 nM).
-
sEH inhibitor-4
0 ImagesCat. No.: HY-147732CAS No.: 2851838-08-7Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.
-
sEH inhibitor-12
0 ImagesCat. No.: HY-151619sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC50 value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC50 value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation.
-
sEH/HDAC6-IN-1
0 ImagesCat. No.: HY-163207CAS No.: 2847838-67-7
-
sEH/HDAC6-IN-2
0 ImagesCat. No.: HY-159171CAS No.: 3009011-58-6sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and HDAC6 inhibitor with IC50s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain.
-
sEH-IN-1
0 ImagesCat. No.: HY-160676CAS No.: 1061377-99-8sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on.
-
SP-C01
0 ImagesCat. No.: HY-173443CAS No.: 2982533-42-4SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and partial PPARγ agonist. SP-C01 can inhibit Ser273 phosphorylation.
-
sEH inhibitor-13
0 ImagesCat. No.: HY-151621sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.4 μM.
-
sEH-IN-22
0 ImagesCat. No.: HY-N16648CAS No.: 2305966-67-8sEH-IN-22 (Compound 1) is a soluble epoxide hydrolase (sEH) inhibitor (IC50 = 1.1 μM) found in Rubia philippinensis. sEH-IN-22 exhibits anti-inflammatory, analgesic and blood pressure-regulating effects. sEH-IN-22 can be used for the researches of inflammation, neurological and cardiovascular disease.
-
SH-11037
0 ImagesCat. No.: HY-182372CAS No.: 1638153-78-2SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization.
